Abstract: The present invention relates to the technical field of biology. Disclosed are a tumor marker, a methylation detection reagent, a kit and application thereof. Disclosed in the present invention is that: a colorectal cancer specimen can be distinguished from a fecal specimen of a normal person by detection a methylation level of COL4A1 gene promoter region. The present invention relates to detecting colorectal cancer by using the methylation detection reagent of the gene.

Abstract: Disclosed are a genetic tumor marker combination, a methylation detection reagent, a kit, and use thereof. Lung cancer specimens can be distinguished by measuring the methylation level of a combination of HOXB4 and SRCIN1 genes. Proved by experiments, the reagent of the present disclosure can detect and diagnose lung cancer, and has clinical application value.

Abstract: Provided are a detection kit and detection method for ITGA4 gene methylation. A primer and a probe provided by the present invention are matched, then detection can be carried out by taking a feces sample as an object, and thus the detection is simple, convenient and rapid. The detection can also be carried out on tissue specimens. Moreover, in the process of detecting the samples, the detection specificity and sensitivity are also improved. The experiment proves that for the feces specimen, when the specificity is 95.2%, the sensitivities of the methylated ITGA4 to intestinal cancer and adenoid tumor are 83.8% and 41.6%, respectively; and for the intestinal cancer tissue, when the specificity is 97.6% (40/41), the detection rates for colorectal cancer and adenoid tumor are 96.2% (101/105) and 71.6% (78/109), respectively. The effects are superior to the detection effects obtained by adopting other primers or probes.

Abstract: Disclosed in the present application are a tumor detection reagent and a kit, comprising a detection reagent for the methylation of a specific nucleic acid fragment, which is used to detect a modified sequence of the specific nucleic acid fragment. The reagent of the present application has passed through experiments and is confirmed to be able to detect and diagnose tumors.

Abstract: The present invention relates to a tumor marker, a methylation detection reagent, a kit and use thereof. By detecting the methylation level of SDC2, COL4A1/COL4A2 and ITGA4 genes, colorectal cancer specimens can be well distinguished from fecal specimens, and the detection sensitivity and specificity for the colorectal cancer can be 90% or above.

Abstract: The present invention relates to the technical field of biology. Disclosed are a tumor marker, a methylation detection reagent, a kit and application thereof. Disclosed in the present invention is that: a colorectal cancer specimen can be distinguished from a fecal specimen of a normal person by detection a methylation level of COL4A1 gene promoter region. The present invention relates to detecting colorectal cancer by using the methylation detection reagent of the gene.

Abstract: The present invention falls within the field of biotechnology, and a tumor marker, a methylation detection reagent, a kit and the use thereof are disclosed. Disclosed in the present invention is that: colorectal cancer specimens can be distinguished from normal human fecal specimens by detecting the methylation level of COL4A2 gene promoter region. The present invention uses a methylation detection reagent of the gene to detect colorectal cancer.

Abstract: The present invention discloses a tumor molecular detection/diagnostic reagent, which takes excrement as a detection sample and includes an SDC2 gene methylation detection reagent. The methylation level of the SDC2 gene detected in the excrement has an extremely high relevance to the onset of the colorectal cancer. The sensitivity of the SDC2 gene in the excrement is 87 percent and the specificity is up to 98 percent or even higher than that in tissue.

Abstract: The present invention discloses a tumor molecular detection/diagnostic reagent, which takes excrement as a detection sample and includes an SDC2 gene methylation detection reagent. The methylation level of the SDC2 gene detected in the excrement has an extremely high relevance to the onset of the colorectal cancer. The sensitivity of the SDC2 gene in the excrement is 87 percent and the specificity is up to 98 percent or even higher than that in tissue.